Diagnostic value of contrast-enhanced ultrasound liver imaging reporting and data system versus European CEUS guidelines for liver malignant tumors

Yali LIU; Guoyu XU; Zhiyan LI; Qian ZHANG; Yi LUAN; Xiaohui LI; Xiaolei WANG

doi:10.16016/j.2097-0927.202208077

您当前的位置：

首页 >

文章列表页 >

Diagnostic value of contrast-enhanced ultrasound liver imaging reporting and data system versus European CEUS guidelines for liver malignant tumors

Clinical Medicine | 更新时间：2026-01-09

- Diagnostic value of contrast-enhanced ultrasound liver imaging reporting and data system versus European CEUS guidelines for liver malignant tumors
- Journal of Army Medical University Vol. 45, Issue 5, Pages: 462-467(2023)
- 作者机构：
  
  1.075000 河北张家口，河北北方学院研究生学院
  2.518112 广东深圳，深圳市第三人民医院放射科
  3.518112 广东深圳，深圳市第三人民医院超声科
- 作者简介：
- 基金信息：
  
  the General Program of National Natural Science Foundation of China(82172563)
- DOI：10.16016/j.2097-0927.202208077
  CLC： R730.41;R735.7
- Received：12 August 2022，
  
  Revised：2022-09-30，
  
  Published：15 March 2023
- 稿件说明：
移动端阅览
Yali LIU, Guoyu XU, Zhiyan LI, et al. Diagnostic value of contrast-enhanced ultrasound liver imaging reporting and data system versus European CEUS guidelines for liver malignant tumors[J]. Journal of Army Medical University, 2023, 45(5): 462-467.
DOI：

Yali LIU, Guoyu XU, Zhiyan LI, et al. Diagnostic value of contrast-enhanced ultrasound liver imaging reporting and data system versus European CEUS guidelines for liver malignant tumors[J]. Journal of Army Medical University, 2023, 45(5): 462-467. DOI： 10.16016/j.2097-0927.202208077.

摘要

目的

对比超声造影肝脏影像报告-数据系统(contrast-enhanced ultrasound liver imaging reporting and data system，CEUS LI-RADS)与欧洲超声造影指南对肝细胞癌(hepatocellular carcinoma，HCC)高危人群肿瘤良恶性鉴别的诊断效能。

方法

筛选2020年8月至2022年1月在深圳市第三人民医院就诊的89例疑似HCC病例的影像学资料，其中男性74例，女性15例，年龄22~77(50.8±11.3)岁。以病理诊断为金标准，采用受试者工作曲线(receiver operating characteristic curve，ROC)分析并计算CEUS LI-RADS和欧洲CEUS指南的ROC曲线下面积(area under the subject curve，AUC)值。计算CEUS LR-5+LR-M与欧洲CEUS指南诊断肝脏恶性肿瘤的敏感性、特异性、阳性预测值、阴性预测值及准确性。

结果

92个病灶中77个病灶经CEUS归类为LR-5+LR-M，77个病灶经欧洲CEUS指南诊断为恶性肿瘤，75个病灶经病理证实为肝脏恶性肿瘤。CEUS LI-RADS和欧洲CEUS指南的AUC值分别为0.875、0.797，差异无统计学意义(

=1.71

=0.088)。以LR-5、LR-M类病灶为阳性结果，CEUS LR-5+LR-M与欧洲CEUS指南诊断肝脏恶性肿瘤的敏感性为97.3%(95%

: 90.7%~99.7%)、94.7%(95%

: 86.9%~98.5%)(χ

=8.12，

=0.004)，特异性为76.5%(95%

: 50.1%~93.2%)、64.7%(95%

: 38.3%~85.8%)，阳性预测值为94.8%、92.2%，阴性预测值为86.7%、73.3%，准确性为93.5%(95%

: 86.3%~97.6%)、89.1%(95%

: 80.9%~94.7%)(χ

=20.63，

＜0.001)。

结论

CEUS LI-RADS与欧洲CEUS指南对HCC高危人群肿瘤良恶性鉴别的诊断效能相当，CEUS LI-RADS的敏感性和准确性更高。

Abstract

Objective

To investigate the diagnostic value of contrast-enhanced ultrasound liver imaging reporting and data system (CEUS LI-RADS) and European CEUS guidelines for liver malignant tumors in high-risk patients with hepatocellular carcinoma (HCC).

Methods

The imaging data of 89 high-risk patients with suspected HCC treated in Shenzhen Third People's Hospital from August 2020 to January 2022 were retrospectively analyzed. They were 74 males and 15 females

and aged between 22 and 77 (50.8±11.3) years. Pathological diagnosis was used as the gold standard

and receiver operating characteristic (ROC) curve analysis was adopted to calculate the areas under the ROC curve (AUC) of CEUS LI-RADS and European CEUS guidlines. And the sensitivity

specificity

positive predictive value (PPV)

negative predictive value (NPV) and accuracy of CEUS LR-5+LR-M and European CEUS guidelines for diagnosing liver malignancies were calculated.

Results

Of the 92 lesions

77 lesions were classified as LR-5+LR-M by CEUS

and 77 lesions were diagnosed liver malignant tumors by European CEUS guidelines

and 75 lesions were pathologically confirmed to be malignant tumors of the liver. The AUC values of CEUS LI-RADS and European CEUS guidelines were 0.875 and 0.797

respectively

through no statistical difference (

=1.71

=0.088). Taking LR-5 and LR-M lesions as positive results

the sensitivity

specificity and PPV

NPV and accuracy were 97.3% (95%

: 90.7%~99.7%) and 94.7% (95%

: 86.9%~98.5%

Chi

-square=8.12

=0.004)

76.5% (95%

: 50.1%~93.2%) and 64.7% (95%

: 38.3%~85.8%)

94.8% and 92.2%

86.7% and 73.3%

and 93.5% (95%

: 86.3%~97.6%) and 89.1% (95%

: 80.9%~94.7%

Chi

-square=20.63

0.001) in CEUS LR-5+LR-M and European CEUS guidelines for diagnosing liver malignancies

respectively.

Conclusion

CEUS LI-RADS shows comparable diagnostic performance as European CEUS guidelines

but the sensitivity and accuracy of CEUS LI-RADS are significantly higher.

关键词

Keywords

references

CRAIG A J, VON FELDEN J, GARCIA-LEZANA T, et al . Tumour evolution in hepatocellular carcinoma[J ] . Nat Rev Gastroenterol Hepatol, 2020, 17(3): 139-152. DOI: 10.1038/s41575-019-0229-4.

中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022年版)[J]. 中华消化外科杂志, 2022, 21(2): 143-168. DOI: 10.3760/cma.j.cn115610-20220124-00053.

Bureau of Medical Administration of National Health Commission of the People's Republic of China. Standardization for diagnosis and treatment of hepatocellular carcinoma (2022 edition)[J]. Chin J Dig Surg, 2022, 21(2): 143-168. DOI: 10.3760/cma.j.cn115610-20220124-00053.

CHEN T J, CHANG X Y, LV K, et al . Contrast-enhanced ultrasound features of intrahepatic cholangiocarcinoma: a new perspective[J ] . Sci Rep, 2019, 9(1): 19363. DOI: 10.1038/s41598-019-55857-6.

WILSON S R, LYSHCHIK A, PISCAGLIA F, et al . CEUS LI-RADS: algorithm, implementation, and key differences from CT/MRI[J ] . Abdom Radiol (NY), 2018, 43(1): 127-142. DOI: 10.1007/s00261-017-1250-0.

DIETRICH C F, NOLSØE C P, BARR R G, et al . Guidelines and good clinical practice recommendations for contrast-enhanced ultrasound (CEUS) in the liver-update 2020 WFUMB in cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS[J ] . Ultrasound Med Biol, 2020, 46(10): 2579-2604. DOI: 10.1016/j.ultrasmedbio.2020.04.030.

American College of Radiology. CEUS LI-RADS v2017 Core[EB/OL]. https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS/CEUS-LI-RADS-v2017.2019.07.19.

ZUO D S, YANG K F, WU S Z. Diagnostic performance of intravascular perfusion based contrast-enhanced ultrasound LI-RADS in the evaluation of hepatocellular carcinoma[J]. Clin Hemorheol Microcirc, 2021, 78(4): 429-437. DOI: 10.3233/CH-211164.

MAKOYEVA A, KIM T K, JANG H J, et al . Use of CEUS LI-RADS for the accurate diagnosis of nodules in patients at risk for hepatocellular carcinoma: a validation study[J ] . Radiol Imaging Cancer, 2020, 2(2): e190014. DOI: 10.1148/rycan.2020190014.

LI S, ZHOU L, CHEN R, et al . Diagnostic efficacy of contrast-enhanced ultrasound versus MRI Liver Imaging Reporting and Data S ystem (LI-RADS) for categorising hepatic observations in patients at risk of hepatocellular carcinoma[J ] . Clin Radiol, 2021, 76(2): 161.e1-161.e10. DOI: 10.1016/j.crad.2020.10.009.

SHIN J, LEE S, BAE H, et al . Contrast-enhanced ultrasound liver imaging reporting and data system for diagnosing hepatocellular carcinoma: a meta-analysis[J ] . Liver Int, 2020, 40(10): 2345-2352. DOI: 10.1111/liv.14617.

FERRAIOLI G, MELONI M F. Contrast-enhanced ultrasonography of the liver using SonoVue[J]. Ultrasonography, 2018, 37(1): 25-35. DOI: 10.14366/usg.17037.

GUO Y Y, QIN X C, CHEN S X, et al . Diagnosis efficacy of CEUS for hepatic inflammatory lesions[J ] . J Clin Lab Anal, 2020, 34(6): e23231. DOI: 10.1002/jcla.23231.

马霞, 胡向东, 谭小蕖, 等. 肝脏局灶性炎性病变的常规超声及超声造影表现[J]. 中国医学装备, 2019, 16(10): 74-77. DOI: 10.3969/J.ISSN.1672-8270.2019.10.021.

MA X, HU X D, TAN X Q, et al . Manifestations of conventional ultrasound and contrast-enhanced ultrasound imaging of focal inflammatory lesion of liver[J ] . China Med Equip, 2019, 16(10): 74-77. DOI: 10.3969/J.ISSN.1672-8270.2019.10.021.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Establishment and application value of a diagnostic model for early hepatic tomors using contrast-enhanced ultrasound based on machine learning

SLC38A1 drives malignant progression of hepatocellular carcinoma by activating PI3K/AKT signaling via enhanced glutamine uptake

Emerging advances in clinical diagnosis and treatment of hepatocellular carcinoma: evolution of comprehensive treatment strategies

PD-L1 promotes hepatocellular carcinoma progression by inhibiting PTP1B and activating FAK

Nuclear EGFR cooperates with YY1 to drive CEMIP expression and enhance hepatocellular carcinoma invasion

Related Author

Li LIU

Ying TAN

Chunlin TANG

Yanli GUO

YANG Yuanyuan

ZHANG Ping

HU Peng

LIU Maonian

Related Institution

Department of Ultrasonography, First Affiliated Hospital

Department of Digital Medicine, Faculty of Biomedical Engineering and Medical Imaging, Army Medical University (Third Military Medical University)

Digestive Disease Center， Chongqing Hygeia Hospital

Department of Hepatobiliary， First Affiliated Hospital， Army Medical University （Third Military Medical University）

Institute of Hepatobiliary Surgery of PLA，First Affiliated Hospital， Army Medical University （Third Military Medical University）

⁰